✦ LIBER ✦

Efficacy and safety of prednisolone in patients with autoimmune hepatitis

✍ Scribed by Keiichiro Yoneyama; Etsuko Honda; Mari Kogo; Yuji Kiuchi; Minoru Shibata; Keiji Mitamura; Michio Imawari

Publisher: Springer Healthcare Communications
Year: 2006
Tongue: English
Weight: 322 KB
Volume: 23
Category: Article
ISSN: 0741-238X
DOI: 10.1007/bf02850349

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment response in patients with auto

Treatment response in patients with autoimmune hepatitis

✍ Christoph Schramm; Christina Weiler-Normann; Christiane Wiegard; Stefanie Hellwe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 1 views

We read with great interest the article by Cavazza et al., 1 who demonstrated that an advanced histological stage was the only risk factor associated with the development of hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) from two European centers. Similar results wer

Disappearance of serum HCV-RNA after sho

Disappearance of serum HCV-RNA after short-term prednisolone therapy in a patient with chronic hepatitis C associated with autoimmune hepatitis-like serological manifestations

✍ Masahide Yoshikawa; Masahisa Toyohara; Yoshiko Yamane; Mayumi Mimura; Yoji Miyam 📂 Article 📅 1999 🏛 Springer Japan 🌐 English ⚖ 257 KB

Efficacy and safety of entecavir versus

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

✍ Yun-Fan Liaw; Maria Raptopoulou-Gigi; Hugo Cheinquer; Shiv Kumar Sarin; Tawesak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 436 KB 👁 2 views

A randomized, open-label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic decompensation (Child-Turcotte-Pugh score ≥7). Adult subjects were randomized and treated (n = 191) with entecavir 1.0 mg or adefovir 10 mg daily for up

Efficacy and safety of peginterferon alp

Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C

✍ Richard Njouom; Michèle Tagni Sartre; Isabelle Timba; Eric Nerrienet; Patrice Tc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract Data were examined from a day‐to‐day clinical practice in Yaounde, Cameroon to evaluate the efficacy and safety of peginterferon alfa‐2a and ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C. Ninety adults with chronic hepatitis C (mean age, 53 ± 8 years; 79% ma

Efficacy of ribavirin in patients with c

Efficacy of ribavirin in patients with chronic hepatitis B

✍ Enrique Galban-García; Hector Vega-Sanchez; Bienvenido Gra-Oramas; Jorge L. Jorg 📂 Article 📅 2000 🏛 Springer Japan 🌐 English ⚖ 89 KB

Efficacy and safety of bortezomib in pat

Efficacy and safety of bortezomib in patients with plasma cell leukemia

✍ Pellegrino Musto; Fausto Rossini; Francesca Gay; Vincenzo Pitini; Tommasina Gugl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract ## BACKGROUND. The prognosis of patients with plasma cell leukemia (PCL), an aggressive variant of multiple myeloma (MM), is usually poor. Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of borte